What is the priority intervention for a patient with pulseless ventricular tachycardia?

PULSELESS VENTRICULAR TACHYCARDIA: A WARNING

There is a danger in thinking that pulseless ventricular tachycardia (VT) is the same a ventricular fibrillation (VF). The electrophysiologic mechanisms of both arrhythmias are different. Although VF always results in pulselessness, VT can have a wide array of effects on perfusion ranging from adequate to no cardiac output. Whenever VT causes inadequate systemic perfusion (is unstable), immediate conversion using electrical counter-shock is indicated.

However, due to the differences in the electrophysiology and myocardial response, termination of fibrillation commonly requires higher therapeutic energy levels, whereas VT is a circuitry issue that most often requires lower therapeutic energy levels to terminate the arrhythmia. Considering that DC counter-shock has been shown to create myocardial damage in some patients, it would seem prudent to be pragmatic about delivered energy and potentially protecting already damaged tissue. If in the case of shockable VT, if a low-energy shock fails, there is always the option to increase joules in a stepwise manner.

The other problem associated with the incorrect concept that “pulseless VT should be treated the same as VF” is refractoriness to shock. This is rarely seen in VT, however commonly seen in VF. Treatment algorithms seem to suggest that if the patient fails to convert with counter-shock in VT, the administration of epinephrine is appropriate. Adding a potent ß1 stimulator in this case could support the anomalous circuitry and hamper further attempts at resuscitation. Additionally, if conversion occurs, the epinephrine could induce a significant tachycardia resulting in further damage to the myocardium. If the goal of the use of epinephrine is enhancement of coronary perfusion pressure, the use of a pure alpha agonist seems more appropriate.

This may be a simple case of trying to “over think” to the point of error. It might serve practitioners well to view VT as “stable” and “unstable”. There is essentially no basic difference in a patient with a heart rate of 180 and a systolic blood pressure of 20mmHg or a patient with a heart rate of 180 and has lost cardiac output. Immediate DC counter-shock is the first step. In cases of incessant reinduction of the VT after a successful conversion, the use of appropriate antiarrhythmic agents make sense. 

Not understanding the differences between VT and VF when called upon the treat these critically ill patients could significantly alter a chance of a good outcome. 

What Are Unstable Ventricular Tachycardias? 

Unstable ventricular tachycardias occur when an anomalous ventricular circuit is activated, reducing cardiac muscle activity, leading to inadequate cardiac output.

The reduction in cardiac output resulting can cause symptoms ranging from decreased level of consciousness to a total lack of cardiac output, known as a pulseless ventricular tachycardia.

Unstable ventricular tachycardia may present with the following characteristics:

  • Broad QRS arrhythmia
  • Highly accelerated heart rates
    • (>180 beats per minute — can become unstable at lower rates)
  • Various levels of perfusion failure (i.e. diaphoresis, confusion, arterial hypotension)
  • Severe signs of heart failure (acute pulmonary edema, severe hypotension)
  • Sudden complete lack of cardiac output (pulselessness) 

Many tachyarrhythmias with heart rates above 150 BPM cause serious impairment of perfusion, especially in patients with pre-existing cardiac dysfunction. However, a patient with an obstructed coronary artery developing ventricular tachycardia (VT) with adequate perfusion, who develops clinical signs of worsening ischemia (i.e. chest pain, etc.) would also be considered having an unstable event. To allow the tachycardia to worsen ischemia and extend an infarct would not be acceptable.

Both narrow QRS and broad QRS tachycardias can produce hemodynamic instability. Thus, from a basic perspective, either can render perfusion inadequate, requiring immediate treatment.

A deeper understanding of arrhythmia recognition allows a practitioner to possibly differentiate between VT and broad QRS atrial fibrillation (AF). This may provide information which could reduce the range of options for treatment to more appropriate solutions, (i.e. VT tends to respond to lower levels of therapeutic electrical therapy, whereas AF often requires higher levels to convert the arrhythmia).

The behavior of the arrhythmia may dictate the best therapy. If the patient is having short episodes of the arrhythmia, followed by spontaneous conversion out of it and returned stability, pharmacologic therapy may be the best course of action, rather than cardioversion.

What Causes Ventricular Tachycardias? 

Ventricular Tachycardias typically emanate from underlying organic disease (acute or chronic), inherited or congenital channelopathies, electrolyte imbalances, or pharmacologic agents.

Some examples of these include: 

Structural Cardiac Disorders 

  • Aortic stenosis
  • Myocardial infarction
  • Congestive heart failure
  • Coronary artery disorder
  • Cardiomyopathy
  • Idiopathic hypertrophic subaortic stenosis (IHSS)

Electrolyte Disturbances

  • Hyperkalemia
  • Hypokalemia
  • Hypocalcemia
  • Hypomagnesemia 

Conduction Defects/Channelopathies

  • AF with anomalous accessory pathways (WPW)
  • Brugada Syndrome
  • Romano-Ward Syndrome
  • Lange-Nielsen Syndrome
  • QT Syndrome

Drugs that result in QT Prolongation

  • Erythromycin
  • Clarithromycin
  • Metoclopramide
  • Haloperidol
  • Droperidol
  • Methadone
  • Antiemetics (ondansetron)
  • Fluoroquinolone antibiotics (ciprofloxacin)
  • Virtually all categories of antiarrhythmic agents can be pro-arrhythmic

Electrophysiologic Phenomena

  • Catecholamine sensitive induced VT/supraventricular tachyarrhythmias (SVT)
  • Wolf-Parkinson-White Syndrome (anomalous accessory pathway conduction) 

Other Causes

  • Pulmonary embolism
  • Cardiac tamponade 
  • Tension pneumothorax (almost always in patients receiving positive airway pressure)
  • Hypothermia
  • Severe acidemia
  • Severe hypoxia
  • Severe hypovolemia

Potential Complications of Unstable / Pulseless VT 

A prolonged, sustained episode of Unstable VT can result in a variety of potential complications, including:

  • Ventricular fibrillation / asystole
  • Cardiac arrest
  • Anoxic brain damage
  • Neurologic injuries
  • Complement activation, coagulation and/or immunologic pathways that may evoke multi-system organ failure and/or adult respiratory distress syndrome (ARDS)
  • Sudden death

Diagnosing Unstable or Pulseless Ventricular Tachycardia

When considering the range of possibilities for treating stable VT, the differentiation of the broad QRS tachycardia is important. However, when either supraventricular tachycardia (SVT) or VT produces hemodynamic or cardiovascular instability, a differential diagnosis is not an instant priority.

Either SVT or VT, when producing instability, require emergency termination of the arrhythmia. In most settings, emergency cardioversion is mandatory. Unless you have a strong reason to believe the underlying mechanism is AF, the majority of circuit/bypass tract mechanisms respond to lower levels of therapeutic energy.

Treatment of Unstable / Pulseless Ventricular Tachycardia

Unstable SVT or VT require emergency countershock. Several misunderstandings are common when discussing details of treatment.

  1. If the patient is in cardiac arrest (pulselessness), perform CPR until arrival of the defibrillator  - see resuscitation sequencing instructions below.
     
  2. When the defibrillator arrives, deliver the counter-shock as soon as possible
    • AED's, depending on the manufacturer, may not be useable when there are organized ECG complexes
    • If one is available, use a manual defibrillator instead
       
  3. If the arrhythmia fails to convert with a lower level of energy, increase the delivered energy for the next shock (most common with broad QRS atrial fibrillation)
    • DO NOT administer epinephrine to a patient who is refractory to a shock
    • In the uncommon situation that the arrhythmia is totally refractory to any level of energy, antiarrhythmic pharmacologic agents can be considered
       
  4. Also continue to assess for underlying conditions preventing a favorable response to electrical therapy

Proper Resuscitation Sequencing

  • Begin CPR if there is no pulse and send for the defibrillator
  • Deliver oxygen and assisted ventilation if required
  • Upon arrival of the defibrillator, place large adhesive patches on the chest (standard placement or anterior-posterior)
  • Set energy to appropriate setting:
    • Broad QRS, regular rhythm: 50 joules *
    • Broad QRS, irregular rhythm: 100-200 joules *
      • NOTE: If a lower level does not cover the arrhythmia, deliver higher energy for the next shock
    • Should the patient convert to ventricular fibrillation (VF), immediately deliver 200 joules on an non-biphasic defibrillator, or 120 joules for biphasic models


* = it is acceptable to use the "synchronized mode" for organized arrhythmias. However, should the patient convert into VF, immediately deliver an NON-SYNCHRONIZED shock (immediate defibrillation) 

Want More Study Resources?

When you register for your exam, you get access to exclusive practice tests and case studies.

Get Access Now

What is the primary treatment for pulseless ventricular tachycardia?

Medical treatment of pulseless VT usually is carried out along with defibrillation and includes intravenous vasopressors and antiarrhythmic drugs. 1 mg of epinephrine IV should be given every 3 to 5 minutes. Epinephrine can be replaced by vasopressin given 40 units IV once.

What is the priority for ventricular fibrillation and pulseless ventricular tachycardia?

Ventricular Fibrillation/Pulseless Ventricular Tachycardia. The most critical interventions during the first minutes of VF or pulseless VT are immediate bystander CPR (Box 1) with minimal interruption in chest compressions and defibrillation as soon as it can be accomplished (Class I).

Which is the priority action of the nurse for a patient with ventricular tachycardia?

CORRECT: A client experiencing ventricular tachycardia who does not have a pulse should receive immediate defibrillation. The earlier defibrillation is performed, the greater the chance the client will survive.

What is the first intervention for V tach?

If you have ventricular tachycardia, you may be given medications called anti-arrhythmics by mouth or IV to slow the fast heart rate. Other heart medications, such as calcium channel blockers and beta blockers, may be prescribed with anti-arrhythmic drugs.